EIK1005

N/A

Report date: 2026/04/09 20:00:21
NME

Base Information

Drug NameEIK1005
Drug Alias NameEIK-1005
ClassificationSmall molecules
Mechanisms of ActionBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN inhibitors
TargetsBifunctional 3'-5' exonuclease/ATP-dependent helicase WRN
Therapy Area/IndicationsSolid tumoursMicrosatellite instability-high cancerMismatch Repair Deficient Cancer +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNew ZealandAustralia
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesEikon Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesEikon Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSolid tumoursMicrosatellite instability-high cancerMismatch Repair Deficient Cancer +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A